Vivio® LVEDP System
Overview
It enables clinicians to measure Left Ventricular End-Diastolic Pressure (LVEDP), which is a critical indicator and clinical hallmark of heart failure. The system utilizes a modified blood pressure cuff, a single-lead ECG, and advanced proprietary algorithms to capture and analyze brachial artery waveforms and heart data.
The Vivio System provides real-time results in less than five minutes, making it suitable for use in primary care settings, cardiology clinics, and even home health care environments. It aims to facilitate earlier detection of heart failure, particularly in high-risk patients, thereby enabling timely initiation of guideline-directed medical therapy (GDMT) and potentially reducing hospitalizations and emergency room visits.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Non-invasive LVEDP measurement
- Aids in early heart failure diagnosis
- Utilizes modified blood pressure cuff and single-lead ECG
- Employs advanced proprietary algorithms for data analysis
- Provides real-time results in under 5 minutes
- Portable for use in clinical or home health care settings
- Demonstrates superior sensitivity compared to echocardiography and BNP tests
- Accurately identifies patients with elevated LVEDP (80% sensitivity, 83% specificity)
- Prompts use of Kansas City Cardiomyopathy Questionnaire 12 (KCCQ-12) for symptom assessment
Use Cases
- Early detection of heart failure in primary care settings
- Screening high-risk patients (e.g., with diabetes or chronic kidney disease) for heart failure
- Monitoring patients in home environments
- Guiding the initiation and titration of guideline-directed medical therapy (GDMT)
- Reducing hospitalizations and emergency room visits due to late-stage heart failure diagnosis
- Improving patient outcomes through earlier intervention
What Physicians Need to Know
The Vivio® System offers a non-invasive, rapid, and accurate method for detecting elevated Left Ventricular End-Diastolic Pressure (LVEDP), a critical indicator of heart failure, directly in primary care and home healthcare settings. This allows for earlier diagnosis and initiation of guideline-directed medical therapy (GDMT), potentially reducing hospitalizations and improving patient outcomes. The system is particularly useful for identifying undiagnosed heart failure in at-risk populations, including those with comorbidities like diabetes and chronic kidney disease. The integration of the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) helps in assessing patient symptoms and disease burden, facilitating appropriate triage and management. While not replacing echocardiography or catheterization, Vivio® provides a more sensitive measurement for early-stage heart failure detection than these traditional methods in an outpatient setting.
The Vivio® System integrates a modified pneumatic brachial blood-pressure cuff and a time-synchronized single-lead ECG to collect data. This data is processed by proprietary algorithms on a mobile tablet application, which also prompts the use of the KCCQ-12 for comprehensive patient assessment. The system is designed for ease of use and mobility, allowing for integration into various healthcare settings, including primary care offices and home healthcare environments.
Details
| Category | Cardiology AI, Wearables & Remote Monitoring (RPM) |
| Pricing | Unknown |
| Compliance | |
| BAA Available | Unknown |
| HIPAA Compliant | Unknown |
| FDA Status | Cleared AI-estimated |
| Integrations | |
| EHR | Not specified |
| Specialties | Cardiology, Emergency Medicine, Internal Medicine |
FDA clearance history
This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.
| Decision date | Number | Name as listed by FDA |
| 2023-10-06 | K223905 510(k) | Vivio® LVEDP System |
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Vivio® LVEDP System
Videos
Product demos, reviews, and walkthroughs for Vivio® LVEDP System.
No videos found. Search YouTube directly





